首页> 外文期刊>Molecular cancer research: MCR >Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor.
【24h】

Transcription-dependent epidermal growth factor receptor activation by hepatocyte growth factor.

机译:转录依赖性表皮生长因子受体被肝细胞生长因子激活。

获取原文
获取原文并翻译 | 示例
           

摘要

The mechanisms and biological implications of coordinated receptor tyrosine kinase coactivation remain poorly appreciated. Epidermal growth factor receptor (EGFR) and c-Met are frequently coexpressed in cancers, including those associated with hepatocyte growth factor (HGF) overexpression, such as malignant astrocytoma. In a previous analysis of the HGF-induced transcriptome, we found that two EGFR agonists, transforming growth factor-alpha and heparin-binding epidermal growth factor-like growth factor (HB-EGF), are prominently up-regulated by HGF in human glioma cells. We now report that stimulating human glioblastoma cells with recombinant HGF induces biologically relevant EGFR activation. EGFR phosphorylation at Tyr(845) and Tyr(1068) increased 6 to 24 h after cell stimulation with HGF and temporally coincided with the induction of transforming growth factor-alpha (~5-fold) and HB-EGF (~23-fold) expression. Tyr(845) and Tyr(1068) phosphorylation, in response to HGF, was inhibited by cycloheximide and actinomycin D, consistent with a requirement for DNA transcription and RNA translation. Specifically, blocking HB-EGF binding to EGFR with the antagonist CRM197 inhibited HGF-induced EGFR phosphorylation by 60% to 80% and inhibited HGF-induced S-G(2)-M transition. CRM197 also inhibited HGF-induced anchorage-dependent cell proliferation but had no effect on HGF-mediated cytoprotection. These findings establish that EGFR can be activated with functional consequences by HGF as a result of EGFR ligand expression. This transcription-dependent cross-talk between the HGF receptor c-Met and EGFR expands our understanding of receptor tyrosine kinase signaling networks and may have considerable consequences for oncogenic mechanisms and cancer therapeutics.
机译:协调受体酪氨酸激酶共激活的机制和生物学意义仍然鲜为人知。表皮生长因子受体(EGFR)和c-Met在癌症中经常共表达,包括与肝细胞生长因子(HGF)过表达相关的那些,例如恶性星形细胞瘤。在先前对HGF诱导的转录组的分析中,我们发现转化生长因子-α和肝素结合表皮生长因子样生长因子(HB-EGF)的两种EGFR激动剂在人类神经胶质瘤中被HGF明显上调。细胞。我们现在报道用重组HGF刺激人胶质母细胞瘤细胞诱导生物学相关的EGFR激活。在用HGF刺激细胞后6至24小时,Tyr(845)和Tyr(1068)的EGFR磷酸化增加,并且在时间上与转化生长因子-α(〜5倍)和HB-EGF(〜23倍)的诱导相符。表达。响应HGF的Tyr(845)和Tyr(1068)磷酸化被环己酰亚胺和放线菌素D抑制,这与DNA转录和RNA翻译的要求一致。具体而言,用拮抗剂CRM197阻断HB-EGF与EGFR的结合将HGF诱导的EGFR磷酸化抑制60%至80%,并抑制HGF诱导的S-G(2)-M过渡。 CRM197还抑制HGF诱导的锚定依赖性细胞增殖,但对HGF介导的细胞保护没有影响。这些发现表明,EGFR配体表达可通过HGF激活EGFR,并产生功能性后果。 HGF受体c-Met与EGFR之间这种依赖转录的串扰扩大了我们对受体酪氨酸激酶信号传导网络的理解,并可能对致癌机制和癌症治疗产生重大影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号